Pancreatic Cancer Research

ResearcherNew York UniversityActive in the last 2 years

Quan Liao

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0001-5999-5602; OpenAlex author ID A5101889542. Sources: OpenAlex.

Their work

Papers
33 (first author 3, last author 7)
Trials
0
Grants
0
Labs led
1
Collaborators
72
Papers, trials and grants by year

2011: 1 paper · 2012: none · 2013: none · 2014: none · 2015: 4 papers · 2016: 3 papers · 2017: 3 papers · 2018: 2 papers · 2019: 2 papers · 2020: 7 papers · 2021: 6 papers · 2022: 1 paper · 2023: 1 paper · 2024: 1 paper · 2025: 1 paper · 2026: 1 paper

Papers 33

  1. Cancer cell-derived sialylated IgG interacting with Siglec-7/9/10 is a potential immunotherapeutic target in pancreatic cancer. Co-author DOI 10.1016/j.xcrm.2026.102660↗
  2. Pancreatic cancer cells escape T/NK cell immune surveillance through the expressional separation of CD58. Co-author DOI 10.1136/jitc-2025-012163↗
  3. Chimeric antigen receptor macrophages targeting c-MET(CAR-M-c-MET) inhibit pancreatic cancer progression and improve cytotoxic chemotherapeutic efficacy. Co-author DOI 10.1186/s12943-024-02184-8↗
  4. Cancer-cell-derived sialylated IgG as a novel biomarker for predicting poor pathological response to neoadjuvant therapy and prognosis in pancreatic cancer. Co-author DOI 10.1097/js9.0000000000000200↗
  5. GREM1 is a novel serum diagnostic marker and potential therapeutic target for pancreatic ductal adenocarcinoma. Last author DOI 10.3389/fonc.2022.968610↗
  6. Dopamine improves chemotherapeutic efficacy for pancreatic cancer by regulating macrophage-derived inflammations. Last author DOI 10.1007/s00262-020-02816-0↗
  7. Comparison of minimal invasive versus open radical antegrade modular pancreatosplenectomy (RAMPS) for pancreatic ductal adenocarcinoma: a single center retrosp… Co-author DOI 10.1007/s00464-020-07938-1↗
  8. Metformin inhibits pancreatic cancer metastasis caused by SMAD4 deficiency and consequent HNF4G upregulation. Co-author DOI 10.1007/s13238-020-00760-4↗
  9. Knockdown of LRRN1 inhibits malignant phenotypes through the regulation of HIF-1α/Notch pathway in pancreatic ductal adenocarcinoma. Last author DOI 10.1016/j.omto.2021.08.012↗
  10. The promoting effects of hsa_circ_0050102 in pancreatic cancer and the molecular mechanism by targeting miR-1182/NPSR1. Last author DOI 10.1093/carcin/bgaa130↗
  11. Comprehensive Analysis of Expression, Prognostic Value, and Immune Infiltration for Ubiquitination-Related FBXOs in Pancreatic Ductal Adenocarcinoma. Last author DOI 10.3389/fimmu.2021.774435↗
  12. Combined blockade of TGf-β1 and GM-CSF improves chemotherapeutic effects for pancreatic cancer by modulating tumor microenvironment. Co-author DOI 10.1007/s00262-020-02542-7↗
  13. Prognostic and predictive value of a five-molecule panel in resected pancreatic ductal adenocarcinoma: A multicentre study. Co-author DOI 10.1016/j.ebiom.2020.102767↗
  14. Surgery for synchronous and metachronous single-organ metastasis of pancreatic cancer: a SEER database analysis and systematic literature review. Co-author DOI 10.1038/s41598-020-61487-0↗
  15. Up-regulation of CDHR5 expression promotes malignant phenotype of pancreatic ductal adenocarcinoma. Last author DOI 10.1111/jcmm.15856↗
  16. Tumor-Associated Macrophages in Pancreatic Ductal Adenocarcinoma: Origin, Polarization, Function, and Reprogramming. Last author DOI 10.3389/fcell.2020.607209↗
  17. Pancreatic Cancer, Gut Microbiota, and Therapeutic Efficacy. Co-author DOI 10.7150/jca.37445↗
  18. CXCL5 overexpression predicts a poor prognosis in pancreatic ductal adenocarcinoma and is correlated with immune cell infiltration. Co-author DOI 10.7150/jca.40517↗
  19. Pancreatic cancer-educated macrophages protect cancer cells from complement-dependent cytotoxicity by up-regulation of CD59. Co-author DOI 10.1038/s41419-019-2065-4↗
  20. Single-cell RNA-seq highlights intra-tumoral heterogeneity and malignant progression in pancreatic ductal adenocarcinoma. Co-author DOI 10.1038/s41422-019-0195-y↗
  21. Tumor size classification of the 8th edition of TNM staging system is superior to that of the 7th edition in predicting the survival outcome of pancreatic canc… Co-author DOI 10.1038/s41598-018-28193-4↗
  22. β1 and β3 integrins in breast, prostate and pancreatic cancer: A novel implication. Co-author DOI 10.3892/ol.2018.8076↗
  23. Interleukin-27 inhibits malignant behaviors of pancreatic cancer cells by targeting M2 polarized tumor associated macrophages. Co-author DOI 10.1016/j.cyto.2015.12.003↗
  24. Chemotherapy and tumor microenvironment of pancreatic cancer. First author DOI 10.1186/s12935-017-0437-3↗
  25. WT1-associated protein is a novel prognostic factor in pancreatic ductal adenocarcinoma. Co-author DOI 10.3892/ol.2017.5784↗
  26. Immunoglobulin G4 (IgG4)-positive plasma cell infiltration is associated with the clinicopathologic traits and prognosis of pancreatic cancer after curative re… Co-author DOI 10.1007/s00262-016-1853-2↗
  27. G-protein-coupled receptor kinase 2 in pancreatic cancer: clinicopathologic and prognostic significance. Co-author DOI 10.1016/j.humpath.2016.06.012↗
  28. Atorvastatin (Lipitor) attenuates the effects of aspirin on pancreatic cancerogenesis and the chemotherapeutic efficacy of gemcitabine on pancreatic cancer by … Co-author DOI 10.1186/s13046-016-0304-4↗
  29. Elevated GRP78 expression is associated with poor prognosis in patients with pancreatic cancer. Co-author DOI 10.1038/srep16067↗
  30. Cancer-associated fibroblasts in pancreatic adenocarcinoma. First author DOI 10.2217/fon.15.176↗
  31. Changes in the Expression of Glucose-regulated Protein 78 in the Occurrence and Progression of Pancreatic Cancer in Mouse Models. Co-author DOI 10.3881/j.issn.1000-503x.2015.03.002↗
  32. HLA-G impairs host immune response and predicts poor prognosis in pancreatic cancer. Co-author PMID 26692947↗
  33. Relationship between single nucleotide polymorphisms in the deoxycytidine kinase gene and chemosensitivity of gemcitabine in six pancreatic cancer cell lines. First author PMID 21362344↗

Closest collaborators

The 25 strongest of 72 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Qiaofei Liu · 17 shared papers, 2015–2025 · strength 2.23
  2. Yupei Zhao · 17 shared papers, 2015–2024 · strength 1.73
  3. Mengyi Wang · 13 shared papers, 2015–2022 · strength 1.22
  4. Ming Cui · 8 shared papers, 2018–2026 · strength 1.09
  5. Sen Yang · 5 shared papers, 2020–2025 · strength 0.92
  6. Ronghua Zhang · 7 shared papers, 2018–2025 · strength 0.88
  7. Yalu Zhang · 5 shared papers, 2021–2025 · strength 0.88
  8. Junyi Gao · 6 shared papers, 2020–2022 · strength 0.79
  9. Junchao Guo · 8 shared papers, 2017–2021 · strength 0.76
  10. Jorg H. Kleeff · 4 shared papers, 2020–2025 · strength 0.66
  11. Taiping Zhang · 7 shared papers, 2017–2021 · strength 0.64
  12. Tong Li · 5 shared papers, 2020–2021 · strength 0.58
  13. Menghua Dai · 6 shared papers, 2018–2021 · strength 0.57
  14. Li Zhou · 8 shared papers, 2015–2020 · strength 0.55
  15. Xiang Zhang · 5 shared papers, 2018–2021 · strength 0.55
  16. Lei You · 6 shared papers, 2015–2021 · strength 0.54
  17. Huaijin Zheng · 2 shared papers, 2024–2025 · strength 0.44
  18. Zheyu Niu · 7 shared papers, 2015–2017 · strength 0.42
  19. Boju Pan · 5 shared papers, 2015–2020 · strength 0.39
  20. Jingkai Liu · 3 shared papers, 2020–2021 · strength 0.31
  21. Lutian Yao · 5 shared papers, 2015–2017 · strength 0.30
  22. Surong Hua · 2 shared papers, 2021 · strength 0.29
  23. Junya Peng · 3 shared papers, 2019–2020 · strength 0.28
  24. Qiaofei Liu · 3 shared papers, 2018–2021 · strength 0.28
  25. Wenming Wu · 3 shared papers, 2019–2021 · strength 0.28

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.